AzTrials
AzTrials

Cystic FibrosisPhase 2NCT02740868

Xenon-129 and Inert Fluorinated Gas Lung MRI: Study of Healthy Volunteers and Participants With Pulmonary Disease

A Phase 2 study testing Xenon-129 and Perfluoropropane (19F), Magnetic Resonance Imaging and Lung Clearance Index in people with Cystic Fibrosis and Asthma, run by The Hospital for Sick Children at 1 site in Canada.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Aim of this study is to evaluate image quality and reproducibility of Xenon-129 and Inert fluorinated (19F) gas Magnetic Resonance Imaging (MRI) and to evaluate changes in lung structure and function in participants with cystic fibrosis (CF) and asthma compared to healthy controls. Read more about this study

Who is it for?
Ages 8 years and olderHealthy volunteers can take part
Conditions the study is for
Cystic Fibrosis, Asthma
What is being tested?
Xenon-129 and Perfluoropropane (19F), Magnetic Resonance Imaging and Lung Clearance Index
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteCanada
Study dates
Aug 2015to 31 Dec 2026
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 8 years and older
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Who may be able to join

  • Participants male and female aged 8 years old and older.
  • Participants have no smoking history.
  • For participants with CF and asthma, a clinical diagnosis is necessary and they should be at their baseline level of symptom control based on history.
  • Participants should have a FEV1%pred value greater than 40%.
  • Participant understands the study procedures and is willing to participate in the study as indicated by signature on the informed consent or assent.
  • Participant must be able to perform a breath hold for 20s or less.
  • Participant able to perform reproducible pulmonary function tests (i.e., the 3 best acceptable spirograms have FEV1 values that do not vary more than 5% of the largest value or more than 100 ml, whichever is greater).
  • For the PEx sub-cohort, admission to the Hospital for Sick Children for a pulmonary exacerbation (based on clinical or pulmonary function assessment). Children who will be admitted and then discharged on home IV antibiotics may also be included in this study.

Who cannot join

  • Participant is, in the opinion of the investigator, mentally or legally incapacitated, preventing informed consent/assent from being obtained, or cannot read or understand the written material.
  • Participant has a history of cardiovascular disorders including coronary insufficiency, cardiac arrhythmias, severe hypertension.
  • Other than for the PEx sub-cohort, participant has had a cold or respiratory infection in the last four weeks.
  • Participant requires supplemental oxygen or has a daytime room air oxygen saturation ≤ 95%.
  • Participant is unable to perform spirometry or plethysmography maneuvers.
  • Participant is pregnant or lactating.
Show all 9Show fewer
  • In the investigator's opinion, participant suffers from any physical, psychological or other condition(s) that might prevent performance of the MRI, such as severe claustrophobia.
  • Participant has an MRI incompatible device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bio prosthetic, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and/or ear implants).
  • -

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Canada1 site, 1 recruiting
  • The Hospital for Sick Children

    Toronto, Ontario, M5G 1X8

    Giles Santyr, PhD FCCPM

    Recruiting

Other trials in Canada

About this study

Official title: Development of Hyperpolarized Xenon-129 and Inert Fluorinated Gas Lung Magnetic Resonance Imaging: Comparative Pilot Study of Healthy Volunteers and Participants With Pulmonary Disease

Aim of this study is to evaluate image quality and reproducibility of Xenon-129 and Inert fluorinated (19F) gas Magnetic Resonance Imaging (MRI) and to evaluate changes in lung structure and function in participants with cystic fibrosis (CF) and asthma compared to healthy controls.

Read the detailed description

Hyperpolarized noble gas magnetic resonance (MR) lung imaging is a relatively new imaging method that allows depiction of both lung function and morphology. Hyperpolarized gases are a new class of MR contrast agent which, when inhaled, provide high temporal and spatial resolution MR images of the lung airspaces. Since no ionizing radiation is involved, hyperpolarized gas MR imaging is ideal for the evaluation of lung diseases especially in children. With hyperpolarized gases, the nuclear spins of the gas atoms are brought into alignment outside of the MR scanner via a process called optical pumping; this yields high polarizations and permits visualization of the lung airspaces with MR imaging (despite the low physical density of the gas in the lung). Two non-radioactive (i.e. stable) isotopes of noble gases helium-3 and xenon-129 can be hyperpolarized. Until recently, higher polarizations could be achieved with helium-3 than with xenon-129, so in humans, helium-3 was more commonly used for hyperpolarized gas MR imaging of the lungs. Recently, the technology has been developed to provide large quantities of highly polarized xenon-129. Helium-3 gas is also extremely expensive and since there are limited reserves of the gas, difficult to procure for research. Unlike helium-3, since xenon-129 is naturally present in the atmosphere, it is less expensive and easier to procure for imaging.

Several applications of xenon-129 MR imaging are under development, including diffusion-weighted and relaxation-weighted imaging. These techniques take advantage of the fact that the rate of loss of xenon-129 polarization is significantly influenced by the local blood flow and concentration of molecular oxygen, as well as the restriction of xenon-129 diffusion by small airway space dimensions. These data can be used to create maps of the lung reflecting regional ventilation/perfusion and micro-airway sizes. Other data that can be obtained with xenon-129 MRI include the volumes of ventilated and unventilated lungs which can subsequently be analyzed to determine the homogeneity of gas distribution within the airspaces. These data can be used to study the structural and functional changes taking place in the lungs associated with pulmonary diseases like CF and asthma. It might provide a diagnostic tool that is able to detect pulmonary diseases more sensitively than the current gold standard measurements of spirometry and plethysmography, and thus prevent irreparable and irreversible damage to the lungs in the early stages of disease.

19F MRI is an emergent technology for the imaging of lung ventilation and function. Similar to HP 129Xe MRI, this technique involves the imaging of an inhaled tracer (inert fluorinated gases) to visualize the airspaces of the lungs. Fluorinated gases such as perfluoropropane have been approved for use as an investigational inhaled contrast at several institutions globally, including a Canadian institution in Thunder Bay, Ontario. Fluorinated gases are non-toxic, commercially available, relatively inexpensive, and have favourable physical/magnetic properties for MRI17-20. Most importantly, unlike 129Xe MRI, fluorinated gases do not require hyperpolarization prior to imaging to boost detectable signal, instead relying on a relatively high number of 19F atoms per molecule and rapid, repeated imaging to enable sufficient signal averaging3. This is a significant advantage compared to HP 129Xe MRI which requires special polarizing equipment; a major barrier to widespread implementation. Despite this, the achievable image quality is generally poorer than 129Xe MRI. Nevertheless, recent improvements in hardware, software and fluorinated gases may enable 19F MRI to provide similar and/or complimentary information compared to HP 129Xe MRI at lower cost and with reduced requirements for hardware and infrastructure21.

Additionally, the paramagnetism of molecular oxygen (O2), which detrimentally impacts the hyperpolarization of 129Xe, does not significantly impact inert fluorinated gases. Therefore, these gases may be prepared in normoxic mixtures prior to administration to participants, rather than in anoxic mixtures as is typically done with 129Xe. This, alongside the fact that irreversible loss of magnetization is not a concern with fluorinated gases, presents the opportunity to perform free-breathing, extended imaging of the lungs. Imaging data acquired during free-breathing can potentially resolve gas kinetics (i.e., gas-wash-in, wash-out, and fractional ventilation)22,23 in a manner that is more feasible and tolerable than with HP noble gases.

Due to the lack of studies evaluating 19F MRI in pediatric lung disease, in this study we aim to develop and test necessary hardware/software for 19F MRI of the lungs children with and without history of respiratory disease and compare to HP 129Xe MRI.

Being tested
Xenon-129 and Perfluoropropane (19F), Magnetic Resonance Imaging, Lung Clearance Index
Keywords
Magnetic Resonance Imaging,cystic fibrosis,asthma,healthy
Medical subject headings
Cystic Fibrosis, Asthma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Xenon-129 and Perfluoropropane (19F)Drug

    Also called 129Xe and 19F

    Xenon gas and perfluoropropane to be inhaled by research participants

  • Magnetic Resonance ImagingDevice

    Also called MRI

    Lung imaging will be performed for participants using MRI for all 3 arms

  • Lung Clearance IndexDevice

    Also called LCI

    Lung clearance index (measure of lung health) will be performed for all participants of all 3 arms

Study groups in NCT02740868
Study groupRoleWhat they receive
HealthyActive comparatorHealthy Participants ages 8 and older. Participants with inhale hyperpolarized xenon-129 which is used as a contrast agent for lung imaging. Perfluoropropane will also be used as a contrast agent for MRI. Perfluoropropane will be inhaled as a normoxic mixture (21% O2 and 79% perfluoropropane). Participants will undergo magnetic resonance imaging and lung clearance index.
Receives: Drug: Xenon-129 and Perfluoropropane (19F); Device: Magnetic Resonance Imaging; Device: Lung Clearance Index
Cystic FibrisosActive comparatorParticipants with cystic fibrosis ages 8 and older.Participants with inhale hyperpolarized xenon-129 which is used as a contrast agent for lung imaging. Perfluoropropane will also be used as a contrast agent for MRI. Perfluoropropane will be inhaled as a normoxic mixture (21% O2 and 79% perfluoropropane). Participants will undergo magnetic resonance imaging and lung clearance index.
Receives: Drug: Xenon-129 and Perfluoropropane (19F); Device: Magnetic Resonance Imaging; Device: Lung Clearance Index
AsthmaActive comparatorParticipants with asthma ages 8 and older.Participants with inhale hyperpolarized xenon-129 which is used as a contrast agent for lung imaging. Perfluoropropane will also be used as a contrast agent for MRI. Perfluoropropane will be inhaled as a normoxic mixture (21% O2 and 79% perfluoropropane). Participants will undergo magnetic resonance imaging and lung clearance index.
Receives: Drug: Xenon-129 and Perfluoropropane (19F); Device: Magnetic Resonance Imaging; Device: Lung Clearance Index

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Significant differences in lung function between CF and healthy group and asthma and healthy group for ventilation defect percent (VDP) measurement

    To evaluate image quality and reproducibility of 129Xe and inert fluorinated (19F) gas MRI and to evaluate changes in lung structure and function in participants with cystic fibrosis (CF) and asthma compared to healthy controls.

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Apr 2016 (estimated)
  2. Study startAug 2015
  3. Primary completion31 Dec 2026 (estimated)
  4. Study completion31 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Diagnosis
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02740868
Sponsor's protocol ID
1000048243
Status last verified
Feb 2026
First submitted
19 Aug 2015
Last updated
2 Mar 2026
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Publications

  • Munidasa S, Couch MJ, Rayment JH, Voskrebenzev A, Seethamraju R, Vogel-Claussen J, Ratjen F, Santyr G. Free-breathing MRI for monitoring ventilation changes following antibiotic treatment of pulmonary exacerbations in paediatric cystic fibrosis. Eur Respir J. 2021 Apr 15;57(4):2003104. doi: 10.1183/13993003.03104-2020. Print 2021 Apr. No abstract available.

    PubMed 33303537
  • Kanhere N, Couch MJ, Kowalik K, Zanette B, Rayment JH, Manson D, Subbarao P, Ratjen F, Santyr G. Correlation of Lung Clearance Index with Hyperpolarized 129Xe Magnetic Resonance Imaging in Pediatric Subjects with Cystic Fibrosis. Am J Respir Crit Care Med. 2017 Oct 15;196(8):1073-1075. doi: 10.1164/rccm.201611-2228LE. No abstract available.

    PubMed 28245140

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Xenon-129 and Perfluoropropane (19F), Magnetic Resonance Imaging and Lung Clearance Index in people with Cystic Fibrosis and Asthma, run by The Hospital for Sick Children at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 2 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Giles Santyr, PhD (416-813-7654 ext. 301394, giles.santyr@sickkids.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Significant differences in lung function between CF and healthy group and asthma and healthy group for ventilation defect percent (VDP) measurement (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02740868, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Mar 2026; AzTrials last refreshed its copy on 7 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in